296 related articles for article (PubMed ID: 8811018)
1. T cell proliferative responses against human papillomavirus type 16 E7 oncoprotein are most prominent in cervical intraepithelial neoplasia patients with a persistent viral infection.
de Gruijl TD; Bontkes HJ; Stukart MJ; Walboomers JM; Remmink AJ; Verheijen RH; Helmerhorst TJ; Meijer CJ; Scheper RJ
J Gen Virol; 1996 Sep; 77 ( Pt 9)():2183-91. PubMed ID: 8811018
[TBL] [Abstract][Full Text] [Related]
2. Lymphoproliferative responses to human papillomavirus (HPV) type 16 proteins E6 and E7: outcome of HPV infection and associated neoplasia.
Kadish AS; Ho GY; Burk RD; Wang Y; Romney SL; Ledwidge R; Angeletti RH
J Natl Cancer Inst; 1997 Sep; 89(17):1285-93. PubMed ID: 9293919
[TBL] [Abstract][Full Text] [Related]
3. Proliferative T cell responses to the human papillomavirus type 16 E7 protein in women with cervical dysplasia and cervical carcinoma and in healthy individuals.
Luxton JC; Rowe AJ; Cridland JC; Coletart T; Wilson P; Shepherd PS
J Gen Virol; 1996 Jul; 77 ( Pt 7)():1585-93. PubMed ID: 8758003
[TBL] [Abstract][Full Text] [Related]
4. Analysis of IgG reactivity against Human Papillomavirus type-16 E7 in patients with cervical intraepithelial neoplasia indicates an association with clearance of viral infection: results of a prospective study.
de Gruijl TD; Bontkes HJ; Walboomers JM; Stukart MJ; Robbesom AA; von Blomberg-van der Flier BM; Herbrink P; Remmink AJ; Verheijen RH; Helmerhorst TJ; Meijer CJ; Scheper RJ
Int J Cancer; 1996 Dec; 68(6):731-8. PubMed ID: 8980175
[TBL] [Abstract][Full Text] [Related]
5. Proliferative T-cell responses to human papillomavirus type 16 E5 are decreased amongst women with high-grade neoplasia.
Gill DK; Bible JM; Biswas C; Kell B; Best JM; Punchard NA; Cason J
J Gen Virol; 1998 Aug; 79 ( Pt 8)():1971-6. PubMed ID: 9714245
[TBL] [Abstract][Full Text] [Related]
6. Human papillomavirus type 16 E6/E7-specific cytotoxic T lymphocytes in women with cervical neoplasia.
Bontkes HJ; de Gruijl TD; van den Muysenberg AJ; Verheijen RH; Stukart MJ; Meijer CJ; Scheper RJ; Stacey SN; Duggan-Keen MF; Stern PL; Man S; Borysiewicz LK; Walboomers JM
Int J Cancer; 2000 Oct; 88(1):92-8. PubMed ID: 10962445
[TBL] [Abstract][Full Text] [Related]
7. Immune responses against human papillomavirus (HPV) type 16 virus-like particles in a cohort study of women with cervical intraepithelial neoplasia. I. Differential T-helper and IgG responses in relation to HPV infection and disease outcome.
de Gruijl TD; Bontkes HJ; Walboomers JM; Coursaget P; Stukart MJ; Dupuy C; Kueter E; Verheijen RH; Helmerhorst TJ; Duggan-Keen MF; Stern PL; Meijer CJ; Scheper RJ
J Gen Virol; 1999 Feb; 80 ( Pt 2)():399-408. PubMed ID: 10073700
[TBL] [Abstract][Full Text] [Related]
8. Phase I/II trial of immunogenicity of a human papillomavirus (HPV) type 16 E7 protein-based vaccine in women with oncogenic HPV-positive cervical intraepithelial neoplasia.
Hallez S; Simon P; Maudoux F; Doyen J; Noël JC; Beliard A; Capelle X; Buxant F; Fayt I; Lagrost AC; Hubert P; Gerday C; Burny A; Boniver J; Foidart JM; Delvenne P; Jacobs N
Cancer Immunol Immunother; 2004 Jul; 53(7):642-50. PubMed ID: 14985860
[TBL] [Abstract][Full Text] [Related]
9. Induction of human papillomavirus-specific CD4(+) and CD8(+) lymphocytes by E7-pulsed autologous dendritic cells in patients with human papillomavirus type 16- and 18-positive cervical cancer.
Santin AD; Hermonat PL; Ravaggi A; Chiriva-Internati M; Zhan D; Pecorelli S; Parham GP; Cannon MJ
J Virol; 1999 Jul; 73(7):5402-10. PubMed ID: 10364287
[TBL] [Abstract][Full Text] [Related]
10. Human papillomavirus type 16-specific T cell responses and their association with recurrence of cervical disease following treatment.
Luxton JC; Nath R; Derias N; Herbert A; Shepherd PS
J Gen Virol; 2003 May; 84(Pt 5):1063-1070. PubMed ID: 12692269
[TBL] [Abstract][Full Text] [Related]
11. CD4+ T cells against human papillomavirus-18 E7 in patients with high-grade cervical lesions associate with the absence of the virus in the cervix.
Seresini S; Origoni M; Caputo L; Lillo F; Longhi R; Vantini S; Paganoni AM; Protti MP
Immunology; 2010 Sep; 131(1):89-98. PubMed ID: 20545782
[TBL] [Abstract][Full Text] [Related]
12. Regression of cervical intraepithelial neoplasia and loss of human papillomavirus (HPV) infection is associated with cell-mediated immune responses to an HPV type 16 E7 peptide.
Kadish AS; Timmins P; Wang Y; Ho GY; Burk RD; Ketz J; He W; Romney SL; Johnson A; Angeletti R; Abadi M;
Cancer Epidemiol Biomarkers Prev; 2002 May; 11(5):483-8. PubMed ID: 12010863
[TBL] [Abstract][Full Text] [Related]
13. Proliferative T cell responses to human papillomavirus type 16 L1 peptides in patients with cervical dysplasia.
Shepherd PS; Rowe AJ; Cridland JC; Coletart T; Wilson P; Luxton JC
J Gen Virol; 1996 Apr; 77 ( Pt 4)():593-602. PubMed ID: 8627247
[TBL] [Abstract][Full Text] [Related]
14. Profiling of serum antibodies against human papillomavirus antigens in Korean women with cervical intraepithelial neoplasia and cervical cancer.
Jin Y; Choi JW; Kim HJ; Eddouzi J; Kim SC; Ju W; Kim YH; Kim HJ
Cancer Med; 2018 Nov; 7(11):5655-5664. PubMed ID: 30353680
[TBL] [Abstract][Full Text] [Related]
15. T-cell response to human papillomavirus type 58 L1, E6, And E7 peptides in women with cleared infection, cervical intraepithelial neoplasia, or invasive cancer.
Chan PK; Liu SJ; Cheung TH; Yeo W; Ngai SM; Cheung JL; Chong P; Man S
Clin Vaccine Immunol; 2010 Sep; 17(9):1315-21. PubMed ID: 20668141
[TBL] [Abstract][Full Text] [Related]
16. Immune responses against human papillomavirus (HPV) type 16 virus-like particles in a cohort study of women with cervical intraepithelial neoplasia. II. Systemic but not local IgA responses correlate with clearance of HPV-16.
Bontkes HJ; de Gruijl TD; Walboomers JM; Schiller JT; Dillner J; Helmerhorst TJ; Verheijen RH; Scheper RJ; Meijer CJ
J Gen Virol; 1999 Feb; 80 ( Pt 2)():409-417. PubMed ID: 10073701
[TBL] [Abstract][Full Text] [Related]
17. Interleukin 2 production in vitro by peripheral lymphocytes in response to human papillomavirus-derived peptides: correlation with cervical pathology.
Tsukui T; Hildesheim A; Schiffman MH; Lucci J; Contois D; Lawler P; Rush BB; Lorincz AT; Corrigan A; Burk RD; Qu W; Marshall MA; Mann D; Carrington M; Clerici M; Shearer GM; Carbone DP; Scott DR; Houghten RA; Berzofsky JA
Cancer Res; 1996 Sep; 56(17):3967-74. PubMed ID: 8752165
[TBL] [Abstract][Full Text] [Related]
18. A phase I trial of a human papillomavirus (HPV) peptide vaccine for women with high-grade cervical and vulvar intraepithelial neoplasia who are HPV 16 positive.
Muderspach L; Wilczynski S; Roman L; Bade L; Felix J; Small LA; Kast WM; Fascio G; Marty V; Weber J
Clin Cancer Res; 2000 Sep; 6(9):3406-16. PubMed ID: 10999722
[TBL] [Abstract][Full Text] [Related]
19. T-cell response to human papillomavirus type 52 L1, E6, and E7 peptides in women with transient infection, cervical intraepithelial neoplasia, and invasive cancer.
Chan PK; Liu SJ; Cheung JL; Cheung TH; Yeo W; Chong P; Man S
J Med Virol; 2011 Jun; 83(6):1023-30. PubMed ID: 21503915
[TBL] [Abstract][Full Text] [Related]
20. Novel oligomannose liposome-DNA complex DNA vaccination efficiently evokes anti-HPV E6 and E7 CTL responses.
Mizuuchi M; Hirohashi Y; Torigoe T; Kuroda T; Yasuda K; Shimizu Y; Saito T; Sato N
Exp Mol Pathol; 2012 Feb; 92(1):185-90. PubMed ID: 22032938
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
